

AMENDMENT

Please amend the specification and claims as follows.

In the Specification.

Please add the following paragraph at the end of the claim set on a separate sheet of paper (new page 35):

ABSTRACT OF THE DISCLOSURE

C₁

This application discloses that inositolphosphoglycans (IPGs) can be obtained from basophils, eosinophils and mast cells and that allergen stimulation of these cells results in IPG release. It also shows that IPGs are second messengers for allergic stimulation as the addition of some types of purified IPGs to non-allergen stimulated cells resulted in histamine release or degranulation. Thus, IPG antagonists can be used for treatment of conditions (especially allergy and asthma) mediated by the release of IPGs from mast cells, basophils or eosinophils. Preferred IPG antagonists include anti-IPG antibodies, inhibitors of the enzyme GPI-PLD and competitive antagonists.

In accordance with 37 CFR §1.121 a marked up version of the above-amended paragraph(s) illustrating the changes introduced by the forgoing amendment(s) is provided in Appendix C.

In the Claims:

Please cancel the following claims: 10-14 and 21-23. ✓ ✓

Please amend the claims by substituting the following claims for the corresponding previously pending claims of the same number(s):

C₂

1. (Amended) A method for making a composition for the treatment of a condition mediated by the release of inositolphosphoglycans (IPGs) from mast cells, basophils or eosinophils, the method comprising providing an effective amount of an IPG antagonist in a pharmaceutically acceptable excipient, wherein the antagonist is:

(a) a substance which is capable of inhibiting release of the IPGs by inhibiting the enzyme GPI-PLD;